| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
3'-Methoxyflavonol targets the neuromedin U 2 receptor (NMU2R), a G protein-coupled receptor involved in the regulation of feeding, energy homeostasis, and stress responses. It is a selective agonist of NMU2R. It has been studied for its ability to scavenge free radicals and modulate signaling pathways involved in inflammation and cancer cell proliferation.
|
|---|---|
| ln Vitro |
3'-Methoxyflavonol (NRA 10) is a neuromedin U 2 receptor (NMU2R) selective agonist [1].
In vitro, 3'-Methoxyflavonol (NRA 10) acts as a selective agonist of the neuromedin U 2 receptor (NMU2R). It has potential antioxidant, anti-inflammatory, and anticancer properties. It can scavenge free radicals, reduce oxidative stress, and modulate various signaling pathways involved in inflammation and cancer cell proliferation. |
| ln Vivo |
In vivo activity data for 3'-Methoxyflavonol are limited. As an NMU2R agonist, it would be expected to modulate feeding, energy homeostasis, and stress responses in vivo. Its antioxidant and anti-inflammatory properties suggest potential in vivo efficacy in models of oxidative stress and inflammation. Further in vivo studies are needed.
|
| Enzyme Assay |
In vitro receptor binding and functional assays for 3'-Methoxyflavonol are conducted using cells expressing recombinant NMU2R. Receptor binding affinity is assessed using radioligand binding assays. Functional activity is measured by calcium mobilization assays or cAMP accumulation assays to determine agonist potency and efficacy.
|
| Cell Assay |
Cellular assays for 3'-Methoxyflavonol are performed using cell lines expressing NMU2R. Cells are treated with compound concentrations ranging from 0.1 nM to 10 µM. Calcium flux is measured using fluorescent calcium indicators such as Fluo-4 AM. Antioxidant activity is assessed by measuring ROS levels using DCFH-DA. Anti-inflammatory activity is assessed by measuring cytokine production.
|
| Animal Protocol |
In vivo animal studies for 3'-Methoxyflavonol would typically utilize rodent models to study its effects on feeding behavior, energy expenditure, and stress responses. The compound is administered orally or intraperitoneally. Endpoints include food intake, body weight, metabolic parameters, and behavioral assessments.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known human metabolites of 3-hydroxy-3p-methoxyflavonoids include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[2-(3-methoxyphenyl)-4-oxochromen-3-yl]oxooxacyclohexane-2-carboxylic acid. Pharmacokinetic properties of 3'-Methoxyflavonol are not well characterized. The compound has a molecular weight of 268.26 and a molecular formula of C16H12O4. As a flavonoid, it is expected to have moderate oral bioavailability and undergo extensive metabolism. Standard PK studies in rodents would be required. |
| Toxicity/Toxicokinetics |
Toxicological data for 3'-Methoxyflavonol are limited. As a naturally occurring flavonoid, it is expected to have a favorable safety profile. No significant acute toxicity has been reported. The compound is designated for research use only.
|
| References | |
| Additional Infomation |
3'-Methoxyflavonol is a selective agonist of the neuromedin U 2 receptor (NMU2R). It has potential antioxidant, anti-inflammatory, and anticancer properties. It has a molecular weight of 268.26 and formula C16H12O4. It is not clinically approved and is used as a research tool for studying NMU2R signaling.
|
| Molecular Formula |
C16H12O4
|
|---|---|
| Molecular Weight |
268.26408
|
| Exact Mass |
268.074
|
| CAS # |
76666-32-5
|
| PubChem CID |
676296
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.353g/cm3
|
| Boiling Point |
435.2ºC at 760 mmHg
|
| Melting Point |
130-131ºC
|
| Flash Point |
164.4ºC
|
| Index of Refraction |
1.651
|
| LogP |
3.174
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
415
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GYLGASXCHFNKHD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O4/c1-19-11-6-4-5-10(9-11)16-15(18)14(17)12-7-2-3-8-13(12)20-16/h2-9,18H,1H3
|
| Chemical Name |
3-hydroxy-2-(3-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~155 mg/mL (~577.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7277 mL | 18.6386 mL | 37.2773 mL | |
| 5 mM | 0.7455 mL | 3.7277 mL | 7.4555 mL | |
| 10 mM | 0.3728 mL | 1.8639 mL | 3.7277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
